The Danish Atrial Fibrillation Registry: A Multidisciplinary National Pragmatic Initiative for Monitoring and Supporting Quality of Care Based on Data Retrieved from Administrative Registries.

The Danish Atrial Fibrillation (AF) Registry monitors and supports improvement of quality of care for all AF patients in Denmark. This report describes the registry's administrative and organizational structure, data sources, data flow, data analyses, annual reporting, and feedback between the registry, clinicians, and the administrative system. We also report the selection process of the quality indicators and the temporal trends in results from 2017-2021. The Danish AF Registry aims for complete registration and monitoring of care for all patients diagnosed with AF in Denmark. Administrative registries provide data on contacts to general practice, contacts to private cardiology practice, hospital contacts, medication prescriptions, updated vital status information, and biochemical test results. The Danish Stroke Registry provides information on stroke events. From 2017 to 2021, the proportion with a reported echocardiography among incident AF patients increased from 39.9% (95% CI: 39.3-40.6) to 82.6% (95% CI: 82.1-83.1). The initiation of oral anticoagulant therapy among patients with incident AF and a CHA Continuous nationwide monitoring of quality indicators for AF originating from administrative registries is feasible and supportive of improvements of quality of care.

Informations de copyright

© 2023 Frost et al.

Déclaration de conflit d'intérêts

L.F reports being supported by a research grant from the Health Research Foundation of Central Denmark Region. Consultant for BMS/Pfizer and AstraZeneca. A.B reports lecture fees from Boehringer-Ingelheim and Bristol-Myers Squibb; research grants from Theravance, The Zealand Region, the Canadian Institutes of Health Research, and the Danish Heart Foundation, grants from Independent Research Fund Denmark outside this work. DD reports lecture fees from BMS and Pfizer. SPJ reports grants from EU, institutional research grant from BMS/Pfizer. Consultant work for BMS/Pfizer. NV reports being supported by a research grant from the Danish Cardiovascular Academy (PD2Y-2022002-DCA). Consultant for AstraZenaca. No fees were received personally. The authors report no other conflicts of interest in this work.